

Jason R. Beckrow, DO FACOI FAAHPM
Assistant Professor MSU COM
Palliative Medicine Medical Director
Karmanos Cancer Institute Lansing

Disclosures None

- Objectives
 - Review the components of a comprehensive pain assessment
 - Review patient factors that influence prescribing in practices
 - Review opiate management practices
 - Oral Morphine Equivalence
 - Opiate Rotation
 - Understand audience perspective
 - Barriers/challenges
 - Proposed solutions

Barriers to Pain Control & Opiate Management

- Fear of diversion
- Fear of overdose
- Fear of substance use disorder
- Fear of legal and regulatory entanglements
- Fear of prescribers' lack of mastery
- Knowledge is necessary to combat Fear
- Absence of an established system for implementation

General Principles

- 1. When in doubt reach out
- 2. What is the source/nature of the patient's pain
- 3. Frequent monitoring and titration are essential
- 4. Calculate Oral Morphine Equivalence OME
- 5. Maximize one opiate before adding another
- 6. Don't forget Tylenol/ NSAIDs and non-opiate analgesics
- 7. Don't forget adjuncts
- 8. Don't forget bowel regimen

General Principles: Opiate Rotation

- 1. Compute OME/MME
- 2. Dose reduce 25-50% for incomplete cross tolerance.
- 3. Long-acting agent 100-66.7% of 24 hour OME
- 4. Short-acting 5-15 % of 24 hours long-acting dose for Break Through Pain BTP
- 5. Frequent monitoring and titration are essential



Equianalgesic Conversion Table

Drug Name	Equian	algesic Dose	Oral to Parenteral Ratio
	Oral (mg)	Parenteral (mg)	
Morphine	25	10	5:2
Hydromorphone	5	2	5:2
Oxycodone	20	n/a	n/a
Hydrocodone	25	n/a	n/a
Oxymorphone	10	1	10:1

Potency ratios:

- → oral morphine: oral hydromorphone is 5:1
- → oral morphine: oral oxycodone is 1.25:1
- → oral morphine: IV hydromorphone is 12.5:1
- → transdermal fentanyl 25mcg/hr: oral morphine 50mg/24hr

Oral hydromorphone is 5 times as potent (mg per mg) as oral morphine

This conversion table is adapted from: McPherson ML. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing, 2nd ed. American Society of Health-System Pharmacists, Bethesda, Maryland, 2018.

Structure Protocol for Choosing the Right Pain Medication

- I. Complete pain assessment
- II. Match the appropriate drug to the pain type
 - o Opiate vs Non-Opiate
 - Short-acting/Long-acting
 - Opiate naïve or not
- III. Consider the risks and side effects
- IV. Assess the safest route of delivery
- V. If rotating opiates, follow guidelines

The Comprehensive Pain Assessment

- I. Discern the characteristic of the patient's pain
 - . Somatic Pain
 - II. Visceral Pain
 - III. Nociceptive Pain
- II. Assess functional history
- III. Review prior drug and non-drug therapy
- IV. Examine the patient and review pertinent data

Somatic Pain

- Caused by tissue damage to skin, soft tissue, muscle or bone
- Described as:
 - Aching
 - Deep
 - Dull
 - Gnawing
 - Sharp
 - Stabbing
- Well-localized patients can often point with one finger to the location of their pain

Visceral Pain

- Pain in the visceral organs such as gallbladder, intestine, liver
- Descriptors:
 - Cramping
 - Squeezing
 - Pressure
 - Full
 - Bloating
 - All-over
 - Gassy
 - May be accompanied by nausea, vomiting or sweating

- Referred:
 - Myocardial infarction jaw or arm pain
 - Kidney stone back pain
 - Liver capsule shoulder
- Colicky severe abdominal pain that comes and goes, may come in waves:
 - Bowel obstruction
 - Gallstone
- Diffuse:
 - Peritonitis
 - Liver metastasis
 - Retroperitoneal adenopathy

Neuropathic Pain

- Injury or inflammation of nerves
- Often coexists with somatic or visceral pain
- Descriptors:
 - Burning
 - Lancing
 - Electric
 - Numb
 - Radiating
 - Shooting
 - Stabbing
 - Tingling
 - Heat
 - Hypersensitive skin

- Distribution
 - Radicular Pain
 - Herpes Zoster
 - Sciatica
 - Stocking Glove
 - Diabetic Neuropathy
 - Chemotherapy induced neuropathy

Structure Protocol for Choosing the Right Pain Medication

- I. Complete pain assessment
- II. Match the appropriate drug to the pain type
 - o Opiate vs Non-Opiate
 - Short-acting/Long-acting
 - Opiate naïve or not
- III. Consider the risks and side effects
- IV. Assess the safest route of delivery
- V. If rotating opiates, follow guidelines





Analgesics Fact Sheet

Acetaminophen	Non-Steroidal Anti-	Opioids	Antiepileptics	Antidepressants	Corticosteroids
	Inflammatory Analgesics				
	(NSAIDS)				

When to Use:

- Indicated for mild to moderate somatic and visceral pain as a single agent or combined with an opioid
- Treats fever, headache, muscle and general pain
- · Oral, liquid, rectal and intravenous formulations
- · Does not affect platelets

When to Avoid:

- Should NOT be used in patients with liver impairment. MONITOR LIVER TESTS
- Narrow therapeutic ratio: Patients should be cautioned and should NOT use more than 4 gram/day (=8 extra strength tablets per 24 hours) WITH close monitoring or 3 gram/day unmonitored. NOTE: 2 extra strength 500 mg acetaminophen (Tylenol) tabs every 6 hours=4 grams. MINOR increases above recommended doses pose serious risk of hepatic necrosis and death

NOTE: Has no anti-inflammatory properties



Acetaminophen	Non-Steroidal Anti- Inflammatory Analgesics	Opioids	Antiepileptics	Antidepressants	Corticosteroids
	(NSAIDS)				

When to Use:

- Indicated for mild to moderate visceral and somatic pain as a single agent or combined with an opioid
- Indicated when treating inflammatory states in the musculoskeletal system
- · Oral, liquid, topical and intravenous formulations

When to Avoid:

- · Bleeding risk, particularly to the gastrointestinal tract
- In combination with other anticoagulants such as warfarin or enoxaparin (Lovenox)
- Low platelet count
- Renal dysfunction
- · Diabetes -high risk of renal dysfunction and failure
- Elderly with creatinine clearance under 30ml/min (common in people over 75 years of age)
- · Congestive heart failure (additive cardiotoxicity and risk of renal failure)
- If patient is already on corticosteroids (increased bleeding risk with no increase in efficacy)

Increased risk of toxicity can occur in the following situations:

- · Higher dose and longer therapy
- · Elderly and medically frail patients
- Patients with renal insufficiency
- Patients with prior gastritis, other gastrointestinal bleeding
- Patients on anticoagulation

Long-term use must be weighed in terms of benefit vs. potential risk.

NOTE:

- · No NSAID has greater analgesic efficacy or safety profile than any other NSAID
- Celecoxib is the only remaining Cox-2 inhibitor on the U.S. market and has not be demonstrated to have greater analgesic efficacy or safety than other NSAIDs



Acetaminophen	Non-Steroidal Anti-	Opioids	Antiepileptics	Antidepressants	Corticosteroids
	Inflammatory Analgesics				
	(NSAIDS)				


When to Use:

- · Indicated for moderate to severe somatic and visceral pain as a single agent or combined with other synergistic drugs
- · Includes dexamethasone (long-acting) and predninsone
- Widely used as a multipurpose analgesic including: bone pain, capsular pain (e.g. liver capsular stretch pain). Headache (raised intracranial pressure), bowel obstruction (due to tumor compression), although evidence base is limited
- · Evidence supports the use of corticosteroids for improved appetite, well-being and fatigue
- · Oral, liquid, intravenous, rectal subcutaneous, depot intramuscular injection formulations

Serious side effects include:

- Early:
 - Agitation
 - Delirium
 - Hyperglycemia
 - Fluid retention
 - Hypertension
 - Increased risk of infection
- Late
 - Adrenal insufficiency
 - Myopathy
 - Hyperglycemia
 - Gl bleeding
 - Avascular necrosis
 - Osteoporosis and fracture
 - Increased risk of infection
- · Should not be combined with NSAIDs-increased risk of GI bleeding with no increase in efficacy





When to Use:

- Indicated for moderate to severe neuropathic pain as a single agent or combined with other synergistic drugs, including gabapentin and pregabalin
- . Mainstay for treatment of neuropathic pain though evidence is mixed
- · Oral formulations only
- Side effects are manageable for most patients

Key Provisos:

- · Dose adjustment in patients with renal failure or renal insufficiency (elderly) for gabapentin and pregabalin
- · Can cause sedation, confusion, ataxia, edema
- Drug-drug interactions are generally well-tolerated



MME/OME

Equianalgesic Conversion Table

Drug Name	Equian	algesic Dose	Oral to Parenteral Ratio
	Oral (mg)	Parenteral (mg)	
Morphine	25	10	5:2
Hydromorphone	5	2	5:2
Oxycodone	20	n/a	n/a
Hydrocodone	25	n/a	n/a
Oxymorphone	10	1	10:1

Potency ratios:

- → oral morphine: oral hydromorphone is 5:1
- → oral morphine: oral oxycodone is 1.25:1
- → oral morphine: IV hydromorphone is 12.5:1
- → transdermal fentanyl 25mcg/hr: oral morphine 50mg/24hr

Oral hydromorphone is 5 times as potent (mg per mg) as oral morphine

This conversion table is adapted from: McPherson ML. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing, 2nd ed. American Society of Health-System Pharmacists, Bethesda, Maryland, 2018.

Case 1

The patient is a 75 year-old male with a diagnosis of metastatic lung cancer with documented bone metastases. He initially presented with mild-to-moderate pain, which was effectively managed with Norco 5/325 mg at a dose of 3 or fewer tablets per day as needed. Over time, the patient reported increasing pain severity, necessitating an increase in his medication frequency and dose. He is now taking two tablets of Norco (10/650 mg total) every four hours, yet he continues to experience significant pain, rated 8/10 on a numerical pain scale.

General Principles: Opiate Rotation

- 1. Compute MME/OME
- 2. Dose reduce 25-50% for incomplete cross tolerance
- 3. Long-acting agent 100-66.7% of 24 hour OME
- 4. Short-acting 5-15 % of 24 hours long-acting dose
- 5. Frequent monitoring and titration are essential

General Principles: Opiate Rotation

1.	Compute MME/OME	60mg
2.	Dose reduce 25-50% for incomplete cross tolerance	45mg

3. Long-acting agent 100-66.7% of 24 hour MME/OME 30 mg

4. Short-acting 5-15% of 24 hours long-acting dose 3-4.5 mg

- 5. MS Contin 15 mg BID
- 6. MS IR 7.5 mg q 4 prn (or)
- 7. Norco 5/325 q 4 prn
- 8. Dexamethasone 4 mg TID
- 9. Senna-S prn
- 10. Frequent monitoring and titration are essential

CAPC Palliative Practice Guidelines. 2015

Case 2

A 63 year-old patient with metastatic breast cancer involving the liver and bones initially had well-controlled pain with oxycodone controlled-release 30 mg TID and oxycodone immediate-release 15 mg Q4H PRN. However, due to escalating pain levels reaching 9/10, an opioid rotation to morphine sulfate extended-release (MS Contin) was considered to optimize analgesia and manage opioid tolerance.

General Principles: Opiate Rotation

- 1. Compute MME/OME
- 2. Dose reduce 25-50 for incomplete cross tolerance
- 3. Long-acting agent 100-66.7% of 24 hour OME
- 4. Short-acting 5-15 % of 24 hours long-acting dose
- 5. Frequent monitoring and titration are essential

General Principles: Opiate Rotation

1. Compute MME/OME

o (30 mg x 3=90) +(15 mg x 6= 90) 180 * 1.25 =

2. Dose reduce 25-50% for incomplete cross tolerance

3. Long-acting agent 100-66.7% of 24 hour OME

4. Short-acting 5-15% of 24 hours long-acting dose

225 mg

168.75 mg

112.5 mg

11.25-16.875 mg

- 5. MS Contin 60 mg BID
- 6. MS IR 15 mg q 2 prn
- 7. Dexamethasone 4 mg tid
- 8. Senna-S prn
- 9. Frequent monitoring and titration are essential

CAPC Palliative Practice Guidelines. 2015

Miscellaneous

- Always add a bowel regimen
- Don't forget about Tylenol and NSAIDS
- Don't forget about Dexamethasone
- Don't forget about adjuncts
- Don't forget about suffering and total pain
 - Anxiety
 - Grief
 - Depression
 - Existential crisis

General Principles

- 1. When in doubt reach out
- 2. What is the source/nature of the patient's pain
- 3. Calculate Morphine Equivalence MME/OME
- 4. Maximize one opiate before adding another
- 5. Frequent monitoring and titration are essential
- 6. Don't forget Tylenol/non-opiate analgesics
- 7. Don't forget adjuncts
- 8. Don't forget bowel regimen

Barriers to Pain Control & Management

- Fear of diversion
- Fear of overdose
- Fear of substance use disorder
- Fear of legal and regulatory entanglements
- Fear of prescribers' lack of mastery
- Armed with Knowledge you can combat Fear
- What is you experience?

References

- Ballantyne JC, Tauben DJ. Expert Decision Making on Opioid Treatment. New York, NY: Oxford University Press: 2013
- Bial A, Paice JA, King L, Fine PG, Levine S. U3: Assessment and Treatment of Physical Pain Associated with Life-Limiting Illness. Glenview, IL: American Academy of Hospice and Palliative Medicine; 2008.
- CAPC. Clinic Practice Guidelines. Opiate Prescribing and Conversions. CAPC.ORG. 2015
- Fine PG, Portenoy RK. Establishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage. 2009; 38(3): 418-425.
- Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9(5):571-91.
- McPherson ML. Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. Bethesda, MD: American Society of Health-System Pharmacists; 2010.
- National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Adult cancer pain: Version 1. 2014. http://oralcancerfoundation.org/treatment/pdf/pain.pdf. Published February 24, 2014. Accessed December 16, 2014.
- Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Medicine. 2012; 13: 562–570.
- WHO's cancer pain ladder for adults. World Health Organization website. http://www.who.int/cancer/palliative/painladder/en/. Accessed December 16, 2014.